Although IFN-α may enhance the sensitivity of osteosarcomas to selected chemotherapeutic agents,34 there are no data demonstrating that IFN-α-2b can be safely administered concurrently with MAP and no data indicating that it would be more efficacious. Here, IFNA2 is linked to osteosarcoma.